Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
Frontiers in Oncology|February 13, 2015
The war on cancer: a military perspectiveBryan Oronsky, Corey A Carter, Vernon Mackie, et al.Translational Oncology|April 27, 2018
A Review of Clinical Radioprotection and Chemoprotection for Oral MucositisBryan Oronsky, Sharad Goyal, Michelle M Kim, et al.Neoplasia (New York, N.Y.)|October 18, 2015
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceBryan Oronsky, Corey A Carter, Tony R Reid, et al.Medical Oncology (Northwood, London, England)|July 6, 2016
Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generationMarcel H Fens, Pedro Cabrales, Jan Scicinski, et al.Journal of Medicinal Chemistry|May 27, 2021
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical DevelopmentBryan Oronsky, XiaoNing Guo, XiaoHui Wang, et al.Biochimica Et Biophysica Acta. Reviews on Cancer|August 23, 2020
COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-makingChristopher Larson, Bryan Oronsky, Sharad Goyal, et al.Biomolecules|July 8, 2016
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming AgentsBryan Oronsky, Jan Scicinski, Michelle M Kim, et al.Oncology Research and Treatment|November 18, 2016
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case ReportChristina Brzezniak, Bryan Oronsky, Jan Scicinski, et al.Future Oncology (London, England)|September 12, 2019
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancerBryan Oronsky, Tony R Reid, Christopher Larson, et al.Clinical Medicine Insights. Oncology|November 15, 2016
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001Bryan Oronsky, Scott Caroen, Karen Zeman, et al.Pageof 4